Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 7;11:7. doi: 10.1038/s41398-020-01156-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a Timeline of experiment and coordinates of infusions for ventral DG and ventral CA1 infusions into FLX non-responders. b Kaplan–Meier survival curve (left panel) and scatterplot (right panel) of NSF data showing individual latency to eat values across all three FLX non-responder treatment groups: vehicle infusions into DG (VEH_DG), Activin A infusions into DG (ACTIVIN_DG), and Activin A infusions into CA1 (ACTIVIN_CA1). c–e One-Way ANOVA of VEH_DG, ACTIVIN_DG, and ACTIVIN_CA1 for: EPM open arm entries and open arm duration (c), FST immobility (d), and Negative Affect Index (e). f Regression analyses correlating NSF latency to eat with EPM open arm duration (left) and FST immobility (right). g Timeline of experiment and coordinates of infusions for ventral DG and ventral CA1 infusions into FLX responders. h Kaplan–Meier survival curve (left panel) and scatterplot (right panel) of NSF data showing individual latency to eat values across all three FLX non-responder treatment groups: vehicle infusions into DG (VEH_DG), Inhibin A infusions into DG (INHIBIN_DG), and Inhibin A infusions into CA1 (INHIBIN_CA1). One-Way ANOVA of VEH_DG, INHIBIN_DG, and INHIBIN_CA1 for: EPM open arm entries and open arm duration (i), FST immobility (j), and Negative Affect Index (k). l Regression analyses correlating NSF latency to eat with EPM open arm duration (left) and FST immobility (right). For survival curves, line shading shows SEM of each group (n = 12 per group). Scatterplots, horizontal lines, and bars show group means with error bars indicating SEM.